Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 7/20 | 0.41 |
| ▸ | TTR | P02766 | 2/20 | 0.39 |
| ▸ | ALB | P02768 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.35 |
| ▸ | ACLY | P53396 | 1/20 | 0.35 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7929409 | 0.84 | GRM5 (0.46) | GRM5TTRALBMEN1KMT2A | |
| SCHEMBL29891425 | 0.78 | GRM5 (0.43) | GRM5TTRALBMEN1KMT2A | |
| SCHEMBL18002603 | 0.78 | TTR (0.41) | TTRALBMEN1KMT2APTPN11 | |
| SCHEMBL8463144 | 0.78 | GRM5 (0.43) | GRM5TTRALBMEN1KMT2A | |
| SCHEMBL16122643 | 0.77 | GRM5 (0.42) | GRM5VCAM1 | |
| SCHEMBL26092693 | 0.75 | TTR (0.48) | TTRALBMEN1KMT2APTPN11 | |
| SCHEMBL29686604 | 0.75 | GRM5 (0.41) | GRM5TTRALBACLYVCAM1 | |
| Water SCHEMBL10768309 | 0.75 | TTR (0.52) | TTRALBMEN1KMT2APTPN11 | |
| SCHEMBL136860 | 0.75 | TTR (0.52) | TTRALBMEN1KMT2APTPN11 | |
| SCHEMBL4897669 | 0.75 | TTR (0.52) | TTRALBMEN1KMT2APTPN11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2026-05-07 | — | — | US | disclosed |
| EP-4658650-A1 | HETEROCYCLIC COMPOUNDS | Beone Medicines I GmbH (CH) | 2025-12-10 | — | — | EP | disclosed |
| US-20250353846-A1 | Heterocyclic Compounds | BEONE MEDICINES I GMBH (CH) | 2025-11-20 | — | — | US | disclosed |
| WO-2024160277-A1 | HETEROCYCLIC COMPOUNDS | BEIGENE, LTD. (KY) | 2024-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260125378-A2 | Heterocyclic Compounds | NFATC1, CD4, MALT1 | GRM5 803/4885TTR 3039/4885ALB 4679/4885 |
| US-20250353846-A1 | Heterocyclic Compounds | NFATC1, CD4, ACIN1 | GRM5 3925/4885TTR 4642/4885ALB 4236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.